Amelia WardA new pill has delivered what oncologists are calling "unprecedented" results in advanced pancreatic cancer. On 31 May 2026, researchers at the American Society of Clinical Oncology (ASCO) annual conference presented phase 3 trial data showing that daraxonrasib, a targeted RAS inhibitor, doubled median survival from 6.6 months to 13.2 months — while producing fewer side effects than standard chemotherapy. The announcement arrived weeks after the UK's Rare Cancers Act 2026 came into force, the first legislation in British history to specifically target pancreatic and other rare cancers.
Why Pancreatic Cancer Has Been So Difficult to Treat
Pancreatic cancer has one of the lowest survival rates of any cancer in the UK. Around 11,000 people die from it every year, and fewer than 8% of patients survive five years after diagnosis. The disease is notoriously hard to detect early: the pancreas sits deep in the abdomen, and early-stage tumours cause no obvious symptoms.
More than 9 in 10 cases are driven by mutations in a family of genes called RAS, which controls how cells grow and divide. For decades, RAS was considered an "undruggable" target. Daraxonrasib — a pan-RAS inhibitor developed by Revolution Medicines — works by blocking the active form of multiple RAS mutations simultaneously, something no previous drug has achieved in a phase 3 setting.
What the Daraxonrasib Trial Results Mean for UK Patients
The phase 3 RASOLUTE trial enrolled patients with advanced pancreatic ductal adenocarcinoma whose cancer had progressed after at least one prior treatment. Participants who received daraxonrasib lived a median of 13.2 months, compared to 6.6 months on standard chemotherapy. The drug is taken as an oral pill, and the trial reported a significantly lower rate of severe side effects than chemotherapy.
As of June 2026, daraxonrasib has received orphan drug designation from the European Medicines Agency (EMA), which entitles the manufacturer to accelerated regulatory support. A UK Medicines and Healthcare products Regulatory Agency (MHRA) application has not yet been submitted. Availability on the NHS is therefore still some time away — but the clinical picture has shifted decisively, and oncologists are being asked about eligibility for expanded access schemes and trials.
Separately, the University of Birmingham opened the first pancreatic cancer mRNA vaccine trial in Europe in early 2026. The personalised vaccine, designed to prevent recurrence in patients who have already undergone surgery, works by training the immune system to recognise cancer-specific proteins on each patient's tumour.
What the Rare Cancers Act 2026 Changes
The Rare Cancers Act 2026 received Royal Assent on 5 March 2026 and came into force on 5 April 2026. It creates three major changes to how rare cancers, including pancreatic cancer, are researched and funded in the UK.
First, it requires a review of UK orphan drug legislation to ensure that Britain remains competitive with the EU and US in attracting pharmaceutical companies to seek UK marketing authorisation. Second, it establishes a National Specialty Lead for Rare Cancers, a dedicated NHS leadership role responsible for accelerating clinical research. Third, it amends the Health and Social Care Act 2012 to allow NHS England to share patient data with researchers to identify potential clinical trial participants.
For patients, this last change is particularly significant. Previously, individuals who might have benefited from a trial were sometimes never contacted, simply because no mechanism existed to match anonymised patient records with trial eligibility criteria.
5 Questions to Ask Your Oncologist Now
The convergence of the daraxonrasib results and the Rare Cancers Act means that a conversation with an oncologist is more productive today than it has been at any previous point. These are the five most important questions to raise:
1. What is my RAS mutation status? Daraxonrasib targets RAS mutations. Knowing which specific mutation is driving your tumour will determine whether you may be eligible for the trial or for future approved treatment.
2. Am I eligible for a daraxonrasib expanded access programme? Before formal approval, pharmaceutical companies sometimes offer compassionate use or expanded access schemes. Your oncologist can check your eligibility.
3. Could I qualify for the Birmingham mRNA vaccine trial? The trial is open to patients who have had surgery for pancreatic cancer. Eligibility criteria include stage of disease and timing of chemotherapy.
4. How does the Rare Cancers Act 2026 affect access to my clinical data? Understanding how your anonymised records may be used to match you with future trials ensures you can make an informed decision about data sharing.
5. Should I seek a second opinion at a specialist centre? Pancreatic cancer care is highly complex, and outcomes vary significantly between general oncology units and specialist hepatopancreatic biliary (HPB) centres. A second opinion is always reasonable.
Early Warning Signs Not to Ignore
Pancreatic cancer is survivable when caught before it spreads, but the window is narrow. According to Pancreatic Cancer UK, symptoms that warrant an urgent GP appointment include new or unexplained jaundice (yellowing of skin or whites of eyes), unexplained weight loss of more than a few kilograms over two months, persistent upper abdominal or back pain, new-onset diabetes in someone over 50 without obvious risk factors, and pale or oily stools.
None of these symptoms is specific to pancreatic cancer, but each justifies a GP consultation and, if indicated, a referral to a specialist.
When to Consult an Oncology Specialist
The NHS referral pathway for suspected pancreatic cancer typically begins with a GP visit. Under the two-week wait (2WW) rule, a GP who suspects cancer must refer you to a specialist within two weeks. If you have already received a diagnosis and want a second opinion on treatment options — particularly given the rapidly changing treatment landscape — a consultation with a specialist oncologist can be arranged privately or through your NHS team.
ExpertZoom connects patients across the UK with oncologists and cancer specialists who can review your case, explain your options, and advise on clinical trial eligibility.
This article is for informational purposes only and does not constitute medical advice. If you have concerns about cancer symptoms, please consult your GP promptly.
